p16 overexpression in malignant and premalignant lesions of the oral and esophageal mucosa following allogeneic hematopoietic stem cell transplantation.
OBJECTIVE
Secondary malignancy in the oral mucosa is recognized as one of the most serious complications in patients who received allogenic hematopoietic stem cell transplantation (HSCT). However, potential risk factors associated with carcinogenesis after HSCT that have been reported remain elusive. We experienced a rare case of secondary malignancies of the oral and esophageal mucosa and analyzed the expression of tumor suppressor gene product p16.


METHODS
A 35-year-old male had malignant lesions of the oral and esophageal mucosa two years after HSCT. Partial maxillectomy and endoscopic submucosal dissection were performed. Immunohistochemical analyses revealed that the tumor cells of malignant and premalignant lesions of the oral cavity and esophagus but not keratosis were positive for p16.


CONCLUSIONS
Pathological examinations with p16 immunohistochemistry may contribute to an early diagnosis of secondary malignancy after HSCT.
Department of Oral and Maxillofacial Surgery, Institute of Clinical Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
Yasumasa
Y
Kakei
Masaya
M
Akashi
Hideki
H
Komatsubara
Tsutomu
T
Minamikawa
Takahide
T
Komori
D000328:Adult; D003131:Combined Modality Therapy; D019941:Cyclin-Dependent Kinase Inhibitor p16; D004938:Esophageal Neoplasms / Q000209:etiology* / Q000378:metabolism; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007150:Immunohistochemistry; D007414:Intestinal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D008223:Lymphoma / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D008297:Male; D009061:Mouth Mucosa / Q000473:pathology; D009062:Mouth Neoplasms / Q000209:etiology* / Q000378:metabolism; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D016609:Neoplasms, Second Primary / Q000209:etiology* / Q000378:metabolism; D011230:Precancerous Conditions / Q000209:etiology* / Q000378:metabolism; D012307:Risk Factors
C000614131:CDKN2A protein, human; D019941:Cyclin-Dependent Kinase Inhibitor p16; D009363:Neoplasm Proteins